Cargando…

Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study

PURPOSE: This study was conducted to determine differences in adverse events associated with the first and second doses of the BNT162b2 coronavirus disease 2019 vaccine based on the age and sex of recipients. MATERIALS AND METHODS: An online survey on the post-vaccination adverse events of healthcar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Yu Min, Lim, Jaegyun, Choe, Kang-Won, Lee, Ki-Deok, Jo, Dong Ho, Kim, Moon Jung, Kim, Jong Min, Kim, Kwang Nam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Vaccine Society 2021
Materias:	COVID-19 Special
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511587/ https://www.ncbi.nlm.nih.gov/pubmed/34703812 http://dx.doi.org/10.7774/cevr.2021.10.3.282

Ejemplares similares

SARS-CoV-2 Antibody Response to the BNT162b2 mRNA Vaccine in Persons with Past Natural Infection
por: Kang, Yu Min, et al.
Publicado: (2021)

Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine
por: Kang, Yu Min, et al.
Publicado: (2021)

A cluster of tertiary transmissions of 2019 novel coronavirus (SARS-CoV-2) in the community from infectors with common cold symptoms
por: Kim, Nam Joong, et al.
Publicado: (2020)

Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination
por: Jo, Dong-Ho, et al.
Publicado: (2021)

Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine
por: Saito, Kazuyuki, et al.
Publicado: (2021)

Spinal cord ischemia complicating BNT162b2 mRNA COVID-19 vaccination
por: Fotiadou, Aggeliki, et al.
Publicado: (2022)

Reactogenicity to COVID-19 vaccination in the United States of America
por: Sanyaolu, Adekunle, et al.
Publicado: (2022)

Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis following third dose of BNT162b2 COVID-19 vaccine in a patient with systemic lupus erythematosus
por: Kang, Minsung, et al.
Publicado: (2023)

Guillain–Barré syndrome associated with BNT162b2 COVID vaccination: a first case report from South Korea
por: Kim, Namkyun, et al.
Publicado: (2022)

Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab
por: Altieri, Manuela, et al.
Publicado: (2022)

COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors
por: Tanzilli, Antonio, et al.
Publicado: (2022)

Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine
por: Trimboli, Michele, et al.
Publicado: (2021)

First manifestation of AQP4-IgG-positive neuromyelitis optica spectrum disorder following the COVID-19 mRNA vaccine BNT162b2
por: Umezawa, Shu, et al.
Publicado: (2022)

In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses
por: Kang, Chang Kyung, et al.
Publicado: (2020)

Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
por: Sauerwein, Kai M.T., et al.
Publicado: (2023)

Selecting coronavirus disease 2019 patients with negligible risk of progression: early experience from non-hospital isolation facility in Korea
por: Choe, Pyoeng Gyun, et al.
Publicado: (2020)

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia
por: Harrington, Patrick, et al.
Publicado: (2021)

Clinical characteristics of coronavirus disease 2019 patients with diarrhea in Daegu
por: Kang, Min Kyu, et al.
Publicado: (2020)

Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales
por: Kerr, Steven, et al.
Publicado: (2022)

Status migrainosus: a potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine—a case report
por: Consoli, Stefano, et al.
Publicado: (2021)

Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability
por: Graydon, Elizabeth K., et al.
Publicado: (2023)

2349. Natural Killer Cells and BNT162b2 mRNA Vaccine Reactogenicity and Durability
por: Graydon, Elizabeth K, et al.
Publicado: (2023)

Dynamics of viral load and anti-SARS-CoV-2 antibodies in patients with positive RT-PCR results after recovery from COVID-19
por: Song, Kyoung-Ho, et al.
Publicado: (2021)

Consensus statement on coronary intervention during the coronavirus disease 19 pandemic: from the Korean Society of Interventional Cardiology
por: Lee, Kwan Yong, et al.
Publicado: (2020)

BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity
por: Vizcarra, Pilar, et al.
Publicado: (2021)

Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa
por: Iannone, Michela, et al.
Publicado: (2021)

Four cases of coronavirus disease 2019 in the early stage of pandemic of South Korea: a single public hospital experience
por: Ahn, Mi Young, et al.
Publicado: (2020)

Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia
por: Santi, Theresia, et al.
Publicado: (2022)

Shingles and mRNA COVID‐19 vaccine
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
por: Bauernfeind, Stilla, et al.
Publicado: (2021)

No evidence of delay in colorectal cancer diagnosis during the COVID-19 pandemic in Gwangju and Jeonnam, Korea
por: Kim, Hye-Yeon, et al.
Publicado: (2022)

The Evolving Policy Debate on Border Closure in Korea
por: Kang, SuJin, et al.
Publicado: (2020)

Persistent severe acute respiratory syndrome coronavirus 2 detection after resolution of coronavirus disease 2019-associated symptoms/signs
por: Park, Se Yoon, et al.
Publicado: (2020)

Lung ultrasound for early diagnosis and severity assessment of pneumonia in patients with coronavirus disease 2019
por: Cho, Young-Jae, et al.
Publicado: (2020)

What should we prepare for the next coronavirus disease 2019 outbreak? A survey on the opinions of infectious diseases specialists in South Korea
por: Kim, Bongyoung, et al.
Publicado: (2020)

Clinical implication and risk factor of pneumonia development in mild coronavirus disease 2019 patients
por: Lee, Hyun Woo, et al.
Publicado: (2021)

Severity of adverse reactions is associated with T-cell response in mRNA-1273 vaccinated health care workers
por: Klingel, Hanna, et al.
Publicado: (2022)

Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases
por: Chantasrisawad, Napaporn, et al.
Publicado: (2022)

The Effects of Border Shutdowns on the Spread of COVID-19
por: Kang, Nahae, et al.
Publicado: (2020)

Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study
por: Hwang, Jong-moon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p56tm1nq785cv7qu1ecml5g86m